[1]闫晓欢,孙乔,吴振华,等.大黄及其中药复方干预肾脏纤维化研究进展[J].陕西中医,2025,46(9):1294-封3.[doi:DOI:10.3969/j.issn.1000-7369.2025.09.029]
　YAN Xiaohuan,SUN Qiao,WU Zhenhua,et al.Research progress of rhubarb and its traditional Chinese medicine compound in intervening renal fibrosis[J].,2025,46(9):1294-封3.[doi:DOI:10.3969/j.issn.1000-7369.2025.09.029]
点击复制

大黄及其中药复方干预肾脏纤维化研究进展

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年9期
页码:
1294-封3
栏目:
综 述
出版日期:
2025-09-05

文章信息/Info

Title:
Research progress of rhubarb and its traditional Chinese medicine compound in intervening renal fibrosis
作者:
闫晓欢1; 孙乔1; 吴振华1; 杨凤文2; 陈素枝2; 檀淼3; 唐淼4; 檀金川2
（1.河北中医药大学研究生学院，河北 石家庄 050091；2.河北中医药大学第一附属医院 河北省中医院，河北 石家庄 050011；3.河北医科大学第四医院，河北 石家庄 050010；4.河北医科大学第二医院，河北 石家庄 050000）
Author(s):
YAN Xiaohuan1; SUN Qiao1; WU Zhenhua1; YANG Fengwen2; CHEN Suzhi2; TAN Miao3; TANG Miao4; TAN Jinchuan2
(1.Graduate School of Hebei University of Traditional Chinese Medicine，Shijiazhuang 050091，China;2.The First Hospital of Hebei University of Chinese Medicine,Hospital of Hebei University of Chinese Medicine Hebei Provincial Hospital of Traditional Chinese Medicine，Shijiazhuang 050011，China;3.The Fourth Hospital of Hebei Medical University，Shijiazhuang 050010，China;4.Second Hospital of Hebei Medical University，Shijiazhuang 050000，China)
关键词:
慢性肾脏病; 肾脏纤维化; 大黄; 中药复方; 研究进展
Keywords:
Chronic kidney disease; Renal fibrosis; Rhubarb; Herbal compound; Research progress
分类号:
R 692
DOI:
DOI:10.3969/j.issn.1000-7369.2025.09.029
文献标志码:
A
摘要:
慢性肾脏病（CKD）是以肾脏的结构、功能进行性恶化为主要临床特征的一种疾病，肾纤维化是CKD进展至慢性肾衰竭(CRF)的必然途径。CRF的治愈目前尚无良策，仅可延缓肾脏纤维化的发展进程。中医药在治疗CKD方面优势突出，具有安全性良好、简便廉验、大众接受度高等优点。近年来随着中医药事业的蓬勃发展，有关大黄及其中药复方治疗CKD的专项研究日益增多。因此，本研究就大黄及其中药复方在抗肾脏纤维化治疗的应用进展方面作一综述，以期为CKD的临床治疗提供借鉴和参考。
Abstract:
Chronic kidney disease (CKD) is a disease with the main clinical characteristics of the structural and functional deterioration of the kidneys,and renal fibrosis is an inevitable pathway for CKD to progress to chronic renal failure (CRF).There is no cure for CRF,but only delaying the development of renal fibrosis.Traditional Chinese medicine (TCM) has outstanding advantages in the treatment of CKD,with the advantages of good safety,simplicity,inexpensive testing,and high public acceptance.In recent years,with the prosperous development of Chinese medicine,more and more special studies have been conducted on the treatment of CKD with rhubarb and its traditional Chinese medicine compound.Therefore,the present study reviews the progress of the application of rhubarb and its herbal formulae in the treatment of anti-renal fibrosis,with a view to providing reference for the clinical treatment of CKD.

参考文献/References:

[1]朱思懿,洪航,边学燕,等.慢性肾脏病流行病学研究进展[J].预防医学,2023,35(9):770-773.
[2]袁玲,王蕾,王宏,等.淫羊藿苷调控TGF-β1诱导的DNA高甲基化抑制5/6肾切除大鼠肾间质肌成纤维细胞增殖研究[J].药物评价研究,2024,47(12):2770-2777.
[3]罗学文,曾玉群,王仕琦,等.大黄颗粒对慢性肾脏病大鼠肠道微生态的影响[J].北京中医药大学学报,2020,43(8):668-674.
[4]金丽霞,金丽军,栾仲秋,等.大黄的化学成分和药理研究进展[J].中医药信息,2020,37(1):121-126.
[5]唐露,司晶,徐寒梅.肾纤维化相关信号通路研究进展[J].药学进展,2021,45(7):532-538.
[6]王静,李玉婷,刘大伟,等.大黄蒽醌类主要有效成分抗肾纤维化作用机制的研究进展[J].中医研究,2023,36(10):92-96.
[7]周姝,董义军,白冰,等.尿毒清颗粒结合复方α-酮酸片对慢性肾衰竭肾功能及血清炎症因子的影响[J].中华中医药学刊,2020,38(11):74-77.
[8]时蔡林,李鹏,魏林.大黄提取物调控p38 MAPK信号通路对慢性肾脏病大鼠肾纤维化的影响[J].中国老年学杂志,2024,44(9):2225-2229.
[9]王延海,张雷明,冯艳艳.大黄素改善高糖条件中人肾小球血管内皮细胞炎症、氧化应激及凋亡作用的研究[J].中国临床药理学杂志,2023,39(10):1422-1426.
[10]周珊珊,艾中柱,李伟男,等.大黄抗肾脏纤维化的网络药理学及其活性成分的作用机制[J].中国实验方剂学杂志,2020,26(10):163-172.
[11]李玉婷,王林群,刘大伟,等.大黄酸通过激活NRF2/HO-1信号通路改善 HK-2人肾小管上皮细胞纤维化的实验研究[J].中药药理与临床,2023,39(11):52-57.
[12]熊浩荣,强淑婷,国慧,等.药材大黄的考证、基原植物资源现状及保护研究[J].时珍国医国药,2021,32(2):424-428.
[13]郭青,何前松,胡斐然,等.大黄酚通过TLR4/NF-κB信号通路途径调控小胶质细胞炎性反应[J].医学信息,2020,33(19):51-54,58.
[14]朱培,闫东梅,郑伟.大黄酚通过抑制巨噬细胞的TNF-α从而改善LPS诱导的小鼠炎症反应[J].中国实验诊断学,2021,25(1):98-101.
[15]刘倩.大黄蛰虫丸对慢性肾衰竭（肾虚血瘀证）患者肾纤维化过程中TGF-β1水平的影响临床观察[D].长沙：湖南中医药大学,2021.
[16]谢帆,吴思雨,许陵冬.大黄蛰虫丸对慢性肾脏病肾脏保护作用的研究进展[J].世界科学技术-中医药现代化,2020,22(6):1803-1806.
[17]张喜奎,宋昱娇,苏明星,等.大黄附子汤加减方治疗慢性肾衰竭大鼠的疗效机制研究[J].亚太传统医药,2024,20(8):17-22.
[18]弓迎宾,任建萍,杨翠玲,等.大黄附子汤保留灌肠治疗慢性肾功能衰竭的观察及评估[J].中国药物与临床,2020,20(21):3581-3582.
[19]王肖志,王晓云.温脾汤加味辅助治疗早中期慢性肾衰竭的效果[J].实用中医内科杂志,2021,35(8):78-80.
[20]肖娟,黄梅,东方梓涵,等.温脾汤“异病同治”慢性肾衰竭、肠易激综合征和消化性溃疡的网络药理学机制探讨[J].空军军医大学学报，2025，46（4）:462-468.
[21]CANAKIS A,HAROON M,WEBER H C.Irritable bowel syndrome and gut microbiota[J].Curr Opin Endocrinol Diabetes Obes,2020,27(1):28-35.
[22]薛春霞,梁建庆,朱向东,等.基于Wnt/β-catenin通路探讨大黄糖络丸对糖尿病肾病db/db小鼠肾纤维化的作用机制[J].中国现代应用药学,2024,41(17):2311-2317.
[23]章溥,梁建庆,杨霞,等.大黄糖络丸调控AGEs/RAGE/IKK/NF-κB通路改善糖尿病肾病小鼠肾脏炎症损伤的机制[J].中国实验方剂学杂志,2024,30(20):77-85.
[24]吕学爱,张鹏,王丽雅.补肾健脾化浊汤辅助治疗慢性肾功能衰竭临床疗效及其对血清肾纤维化指标的影响[J].山东医药,2021,61(14):62-64.
[25]郭建勋.健脾补肾降浊方治疗早期糖尿病肾病脾肾气虚证的临床研究[D].晋中：山西中医药大学,2019.
[26]张新志,董飞侠,钱玲,等.抗纤灵冲剂调控基因与蛋白表达干预肾间质纤维化的机制研究[J].辽宁中医杂志,2022,49(1):173-176.
[27]吴振华,曹雯萱,檀淼,等.基于mTORC1/p70 S6K通路探讨大黄泄浊方对慢性肾衰竭大鼠自噬和凋亡的影响[J].时珍国医国药,2023,34(2):321-324.
[28]张欣欣,辛鑫,吴振华,等.大黄泄浊方对5/6肾切除大鼠肾脏保护作用及对PERK/ATF4/CHOP通路的影响[J].时珍国医国药,2022,33(12):2908-2913.
[29]宋坚,王旭东,刘宏斌,等.肾安方对慢性肾脏病大鼠EGFR介导的PI3K/AKT通路的影响[J].中医药导报,2022,28(8):22-26.
[30]宋坚,王旭东,郑炜贞,等.肾安方对慢性肾脏病大鼠Hedgehog信号通路的影响[J].辽宁中医杂志,2024,51(12):192-196,241-243.
[31]赵瑾,袁立英,罗亚舟,等.尿毒清颗粒联合左卡尼汀对维持性血液透析患者营养不良、微炎症状态及生活质量的影响[J].中华中医药学刊,2020,38(3):107-110.
[32]李冉.尿毒清颗粒联合复方α-酮酸片治疗肾衰竭对肾功能的保护作用[J].罕少疾病杂志,2024,31(7):79-81.
[33]蔡菁菁.肾康注射液对糖尿病肾病患者微炎性反应与肾脏血流的影响观察[J].中国医学创新,2021,18(17):92-96.
[34]崔天梦,黄更珍,张莹莹,等.肾康注射液调节TGF-βⅠ型受体/Smad通路抑制肾纤维化的作用机制[J].世界科学技术-中医药现代化,2023,25(10):3355-3363.
[35]兰欣蓉,卫雅妮,范国荣,等.基于Shh/Gli1信号通路探讨肾衰宁颗粒对5/6肾切除肾衰竭模型大鼠肾间质纤维化的影响[J].中国中西医结合肾病杂志,2023,24(8):674-678,755.
[36]李国辉,王俊霞,卢甜美,等.肾衰宁颗粒联合前列地尔治疗慢性肾衰竭的临床研究[J].现代药物与临床,2020,35(11):2212-2215.

相似文献/References:

[1]屈 凯,王悦彤,王漱非,等.基于文献研究探讨益肾散结法防治肾小球硬化的理论内涵*[J].陕西中医,2019,(7):919.
　QU Kai,WANG Yuetong,WANG Shufei,et al.Based on literature research to explore the theoretical connotation of Kidney-reinforcing and Mass-disintegrating for prevention and treatment of glomerulosclerosis[J].,2019,(9):919.
[2]任永朋,华 琼,刘彦妍,等.中医“治未病”思想在防治肾脏病中的应用*[J].陕西中医,2019,(8):1101.
　REN Yongpeng,HUA Qiong,LIU Yanyan,et al.The application of the thought of “preventive treatment of disease” in the prevention and treatment of kidney disease in traditional Chinese medicine[J].,2019,(9):1101.
[3]张宏强,李桂霞,章彩凤,等.许筠治疗慢性肾病临床药对举隅*[J].陕西中医,2020,(6):808.[doi:DOI:10.3969/j.issn.10007369.2020.06.031]
[4]陈紫薇,陈 明△.从脾论治慢性肾脏病的生物学基础探讨*[J].陕西中医,2020,(11):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
　CHEN Ziwei,CHEN Ming..Discuss the biological foundation for chronic disease therapy from treatment through the spleen[J].,2020,(9):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
[5]董 怡,马 静,余楠楠,等.大黄复方保留灌肠辅助治疗慢性肾脏病疗效及对患者生活质量的影响[J].陕西中医,2021,(7):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
　DONG Yi,MA Jing,YU Nannan,et al.Effect analysis of rhubarb compound retention enema adjuvant treatment of chronic kidney disease and its impact on patients' quality of life[J].,2021,(9):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
[6]齐 宁,宋姝西,刘香玉,等.参芪延肾方治疗慢性肾脏病疗效及对患者半乳糖缺陷IgA1、晚期糖基化终产物和微炎性反应状态的影响[J].陕西中医,2022,(5):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
　QI Ning,SONG Shuxi,LIU Xiangyu,et al.Effects of Shenqi Yanshen recipe on the levels of Gd-IgA1,AGEs and micro inflammatory response in patients with chronic kidney disease[J].,2022,(9):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
[7]麦芳雄,张香兰,朱德礼.温肾健脾清化汤辅助治疗脾肾气虚型慢性肾脏病疗效及对患者血清转化生长因子β1、纤维连接蛋白水平的影响[J].陕西中医,2022,(8):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
　MAI Fangxiong,ZHANG Xianglan,ZHU Deli.Clinical efficacy of Wenshen Jianpi Qinghua decoction in the treatment of chronic kidney disease with spleen-kidney qi deficiency and its effect on serum transforming growth factor β1 and fibronectin levels[J].,2022,(9):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
[8]杨淑彬,李 婷,李晓妮,等.不同中药结肠透析模式对慢性肾脏病患者胃肠道症状和营养状态的影响[J].陕西中医,2022,(12):1698.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.010]
　YANG Shubin,LI Ting,LI Xiaoni,et al.Effects of different colon dialysis modes of traditional Chinese medicine on gastrointestinal symptoms and nutritional status in patients with chronic kidney disease[J].,2022,(9):1698.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.010]
[9]陈 曦,董凯旋,周 荣,等.中药调控p38丝裂原活化蛋白激酶/核因子κB通路治疗肾纤维化研究进展[J].陕西中医,2023,(7):980.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.036]
　CHEN Xi,DONG Kaixuan,ZHOU Rong,et al.Research progress of traditional Chinese medicine regulating p38MAPK/NF-κB pathway in treatment of renal fibrosis[J].,2023,(9):980.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.036]
[10]周 林,禹 红,刘毓玲,等.活肾通络方联合依那普利对慢性肾脏病患者纤维化标志物、人附睾蛋白4水平的影响[J].陕西中医,2023,(10):1400.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.014]
　ZHOU Lin,YU Hong,LIU Yuling,et al.Effect of Huoshen Tongluo decoction and enalapril on renal function,fibrosis markers and HE4 levels in patients with chronic renal disease[J].,2023,(9):1400.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.014]

备注/Memo

备注/Memo:
国家自然科学基金资助项目（82405075）；河北省自然科学基金资助项目（H2023423086）；政府资助临床优秀人才培养项目（ZF2024165）
更新日期/Last Update: 2025-09-08